Duality Advisers LP Purchases New Stake in Enovis Co. (NYSE:ENOV)

Duality Advisers LP purchased a new stake in Enovis Co. (NYSE:ENOV) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,291 shares of the company’s stock, valued at approximately $296,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ENOV. Vanguard Group Inc. raised its stake in Enovis by 1.1% during the third quarter. Vanguard Group Inc. now owns 4,897,449 shares of the company’s stock worth $258,242,000 after acquiring an additional 51,319 shares in the last quarter. Diamond Hill Capital Management Inc. raised its stake in Enovis by 9.9% during the third quarter. Diamond Hill Capital Management Inc. now owns 2,429,173 shares of the company’s stock worth $128,090,000 after acquiring an additional 219,659 shares in the last quarter. DAVENPORT & Co LLC raised its stake in Enovis by 12.6% during the fourth quarter. DAVENPORT & Co LLC now owns 1,879,425 shares of the company’s stock worth $105,920,000 after acquiring an additional 210,358 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Enovis by 0.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,031,710 shares of the company’s stock worth $57,796,000 after acquiring an additional 4,274 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in Enovis by 0.8% during the third quarter. Principal Financial Group Inc. now owns 832,415 shares of the company’s stock worth $43,893,000 after acquiring an additional 6,353 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on ENOV shares. Stephens started coverage on Enovis in a report on Tuesday, February 13th. They set an “overweight” rating and a $72.00 price target on the stock. Canaccord Genuity Group boosted their price target on Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Wells Fargo & Company boosted their price target on Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. UBS Group started coverage on Enovis in a report on Monday, January 22nd. They set a “buy” rating and a $75.00 price target on the stock. Finally, William Blair started coverage on Enovis in a report on Wednesday, January 3rd. They set an “outperform” rating on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $75.43.

Enovis Stock Performance

Shares of ENOV stock opened at $55.23 on Friday. The business’s 50 day simple moving average is $59.95 and its 200 day simple moving average is $55.48. Enovis Co. has a one year low of $43.04 and a one year high of $66.14. The stock has a market capitalization of $3.03 billion, a PE ratio of -90.54 and a beta of 1.97. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.43 and a quick ratio of 1.16.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, February 22nd. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.76 by $0.03. The business had revenue of $455.00 million for the quarter, compared to analysts’ expectations of $444.34 million. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. The firm’s revenue was up 11.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.72 earnings per share. As a group, research analysts forecast that Enovis Co. will post 2.58 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.